Amy Marcus of the The Wall Street Journal featured the Andrews’ journey with Niemann-Pick Type C (NPC) and the investigational medication referred to as Adrabetadex (VTS-270). The article also highlighted the devastating setback the NPC Community is facing due to the discontinuation of the NPC program by Mallinckrodt Pharmaceuticals.
View Complete Story